Avalo Therapeutics SG&A Expense (Quarterly) Analysis

Avalo Therapeutics Inc (AVTX)

13.50 -0.01 (-0.07%) USD | NASDAQ | May 07, 16:00

13.33 -0.17 (-1.26%) After-Hours: 20:00

SG&A Expense (Quarterly) Chart

Historical SG&A Expense (Quarterly) Data

View and export this data back to 2014. Upgrade now.

Date	Value
December 31, 2023	2.676M
September 30, 2023	2.49M
June 30, 2023	2.427M
March 31, 2023	2.708M
December 31, 2022	2.959M
September 30, 2022	3.284M
June 30, 2022	2.784M
March 31, 2022	11.68M
December 31, 2021	5.981M
September 30, 2021	5.926M
June 30, 2021	7.404M
March 31, 2021	5.346M
December 31, 2020	4.617M
September 30, 2020	5.035M
June 30, 2020	6.754M
March 31, 2020	3.353M
December 31, 2019	3.017M
September 30, 2019	2.852M
June 30, 2019	2.667M
March 31, 2019	3.072M

Date	Value
December 31, 2018	-2.666M
September 30, 2018	4.195M
June 30, 2018	5.084M
March 31, 2018	4.444M
December 31, 2017	3.590M
September 30, 2017	2.152M
June 30, 2017	1.439M
March 31, 2017	1.330M
December 31, 2016	1.094M
September 30, 2016	1.703M
June 30, 2016	1.637M
March 31, 2016	2.649M
December 31, 2015	1.924M
September 30, 2015	0.7217M
June 30, 2015	1.016M
March 31, 2015	0.7608M
December 31, 2014	1.574M
September 30, 2014	1.628M
June 30, 2014	0.7945M
March 31, 2014	0.8791M

SG&A Expense Definition

SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

Read full definition.

SG&A Expense (Quarterly) Range, Past 5 Years

2.427M

Minimum

Jun 2023

11.68M

Maximum

Mar 2022

4.419M

Average

3.284M

Median

Sep 2022

SG&A Expense (Quarterly) Benchmarks